Gilead Sciences, Inc. $GILD Shares Sold by GC Wealth Management RIA LLC

by · The Cerbat Gem

GC Wealth Management RIA LLC lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 78.3% in the 4th quarter, HoldingsChannel reports. The fund owned 4,627 shares of the biopharmaceutical company’s stock after selling 16,685 shares during the period. GC Wealth Management RIA LLC’s holdings in Gilead Sciences were worth $568,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Corundum Trust Company INC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth about $26,000. Ares Financial Consulting LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $28,000. Financial Consulate Inc. boosted its position in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 109 shares in the last quarter. MTM Investment Management LLC boosted its position in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares in the last quarter. Finally, BOCHK Asset Management Ltd acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $31,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. BMO Capital Markets upped their price objective on Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 26th. Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 14th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, April 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $157.35.

Read Our Latest Report on Gilead Sciences

Gilead Sciences Stock Up 1.6%

GILD stock opened at $130.84 on Friday. The company has a fifty day moving average price of $140.49 and a 200 day moving average price of $132.35. Gilead Sciences, Inc. has a 12 month low of $95.29 and a 12 month high of $157.29. The company has a market cap of $162.40 billion, a price-to-earnings ratio of 19.33, a price-to-earnings-growth ratio of 1.70 and a beta of 0.39. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the prior year, the firm earned $1.90 EPS. Gilead Sciences’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were paid a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.5%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.45%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the chief financial officer directly owned 176,191 shares of the company’s stock, valued at $24,835,883.36. This represents a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the insider directly owned 128,779 shares of the company’s stock, valued at approximately $18,152,687.84. This represents a 2.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 178,640 shares of company stock valued at $26,584,250 in the last ninety days. Insiders own 0.30% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

  • Positive Sentiment: FDA granted priority review for Gilead’s once‑daily bictegravir + lenacapavir (BIC/LEN) NDA with an August PDUFA date — this speeds potential U.S. commercialization and reduces regulatory timing risk if approved. FDA Grants Priority Review for BIC/LEN
  • Positive Sentiment: Morgan Stanley bumped its price target to $175 and kept an overweight rating — a high‑profile analyst upgrade that can attract institutional interest and support further upside. Morgan Stanley Raises PT to $175
  • Positive Sentiment: Gilead completed the Arcellx acquisition (~$7.8B), adding the anito‑cel cell therapy to its oncology pipeline — expands long‑term growth optionality beyond antivirals. Gilead Completes Arcellx Acquisition
  • Positive Sentiment: Technical analysts point to a long‑term breakout retest (an 11‑year cup base) implying ~35% upside if it holds — this can trigger momentum/quant buying. Gilead Crosses Critical Breakout Level
  • Neutral Sentiment: Wall Street still tilted bullish overall (many buy/overweight ratings; analysts expect earnings growth) — supportive backdrop but consensus already prices some upside. Wall Street Outlook on Gilead
  • Neutral Sentiment: Gilead is due to report earnings next week with street models calling for growth — an earnings beat could extend the rally, a miss could reverse gains. Earnings Preview: Street Expects Growth
  • Neutral Sentiment: Small analyst estimate tweaks and sector ETF flow commentary may drive short‑term volatility but are not company‑specific catalysts. Sector Context & ETF Flows
  • Negative Sentiment: CEO Daniel O’Day sold 10,000 shares under a pre‑arranged 10b5‑1 plan — insider selling can create near‑term headline pressure even if routine. SEC Form 4: O’Day Sale
  • Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking more transparency on patent exclusivities — could raise governance/IP uncertainty and headline risk around future exclusivity revenue. AHF Shareholder Resolution on Patents

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Read More

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).